JP2003528155A5 - - Google Patents

Download PDF

Info

Publication number
JP2003528155A5
JP2003528155A5 JP2001570294A JP2001570294A JP2003528155A5 JP 2003528155 A5 JP2003528155 A5 JP 2003528155A5 JP 2001570294 A JP2001570294 A JP 2001570294A JP 2001570294 A JP2001570294 A JP 2001570294A JP 2003528155 A5 JP2003528155 A5 JP 2003528155A5
Authority
JP
Japan
Prior art keywords
antibody
variant
fragment
day
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001570294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/009413 external-priority patent/WO2001072333A1/en
Publication of JP2003528155A publication Critical patent/JP2003528155A/ja
Publication of JP2003528155A5 publication Critical patent/JP2003528155A5/ja
Pending legal-status Critical Current

Links

JP2001570294A 2000-03-24 2001-03-23 Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法 Pending JP2003528155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19204700P 2000-03-24 2000-03-24
US60/192,047 2000-03-24
PCT/US2001/009413 WO2001072333A1 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Publications (2)

Publication Number Publication Date
JP2003528155A JP2003528155A (ja) 2003-09-24
JP2003528155A5 true JP2003528155A5 (enExample) 2008-04-17

Family

ID=22708018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001570294A Pending JP2003528155A (ja) 2000-03-24 2001-03-23 Ｃｄ２０に対する抗体とインターロイキン−２との組み合わせを用いる非ホジキンリンパ腫の治療方法

Country Status (7)

Country Link
US (1) US20020009427A1 (enExample)
EP (1) EP1267927A1 (enExample)
JP (1) JP2003528155A (enExample)
AU (1) AU2001247737A1 (enExample)
CA (1) CA2404390A1 (enExample)
IL (1) IL151906A0 (enExample)
WO (1) WO2001072333A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020027311A (ko) 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
PT1255558E (pt) * 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
JP2005538034A (ja) * 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
AU2015205832A1 (en) * 2002-10-17 2015-08-13 Genmab A/S Human Monoclonal Antibodies Against CD20
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
HRP20090325T1 (en) 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
BRPI0510224A (pt) * 2004-05-05 2007-10-23 Genentech Inc métodos de prevenção de doença autoimunológica e artigo industrializado
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
AU2005251764A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
SG165344A1 (en) * 2004-10-05 2010-10-28 Genentech Inc Method for treating vasculitis
WO2006076651A2 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2318048B1 (en) * 2008-07-21 2019-05-29 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
CN102050879B (zh) * 2009-10-30 2014-02-19 上海抗体药物国家工程研究中心有限公司 抗人cd20人源化抗体、其制备方法及用途
TWI522941B (zh) * 2009-12-15 2016-02-21 古維拉知識產權股份有限公司 用以產生及顯示代表品牌個性之內容的系統及方法
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
WO2013177187A2 (en) * 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法

Similar Documents

Publication Publication Date Title
JP2003528155A5 (enExample)
JP2004501101A5 (enExample)
NZ505877A (en) Oral delivery of nucleic acid vaccines by particulate complexes
Barry et al. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
HK1052301A1 (zh) α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
WO1994011026A3 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
MXPA05007211A (es) Composicion farmaceutica que comprende una region de fc de inmunoglobulina como un vehiculo.
JP2003500040A5 (enExample)
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2005007673A3 (en) Immunogenic peptides
JP2016514132A5 (enExample)
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
IL171991A0 (en) Use of an interferon polypeptide in the preparation of a pharmaceutical composition for treating virus infection and a method of treating a virus-infected non human subject
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
IL177069A (en) ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CA2452986A1 (en) Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2007145760A3 (en) Anthrax compositions and methods of use and production
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
JP2006502228A5 (enExample)
JP2003514025A5 (enExample)